EGFR and esophageal squamous cell carcinoma: However, TKIs or EGFR antibodies, such as gefitinib and cetuximab, respectively, have exhibited limited or no clinical benefits for ESCC patients (9, 10), implying the necessities of further understanding EGFR regulation in ESCC cells in order to develop improved or new strategies targeting EGFR as therapeutic measures for ESCC patients.